$COMM

Secondaries announced 11.10.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sanchez Production Symbol: SPP Price: $16.00-$18.00 Last trade $14.20 Trade Date: 11/17 Shares: 8.8 million Underwriter(s)Citi, RBC, BofA Merrill Lynch, Johnson[…]

Secondaries announced 9.20.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: CareDx Symbol: CDNA Price: Last trade $4.30 Description: No re-offer available Trade Date: 9/21 Shares: 2.3 million Underwriter(s) Piper Jaffray Rating=Subscription[…]

Secondaries announced 8.23.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: CommScope Holding Company Symbol: COMM Price: Last trade $29.19 Description: Re-offer $29.19 Trade Date: 8/24 Shares: 7 million Underwriter(s) Credit Suisse[…]

Secondaries announced 5.02.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sterling Construction Symbol: STRL Price: Last trade $5.24 Trade Date: 5/4 Shares: 4.5 million Underwriter(s) D.A. Davidson Rating=Subscription Needed Company: EQT[…]

Secondaries announced 6.10.2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: BioPharmx Symbol: BPMX Price: $3.00-$3.00 Description: They are a specialty pharmaceutical company focused on utilizing our proprietary drug delivery technologies to[…]

Scroll to top
error: Content is protected !!